Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

    Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

    Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

    We pioneer breakthroughs in healthcare. For everyone. Everywhere. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

    1. Home

    2. Perspectives

    3. PSMA: A Windfall for PET/CT Imaging

    PSMA: A Windfall for PET/CT Imaging

    4min
    Hildegard Kaulen
    Published on August 23, 2017
    Professor Klaus Kopka, MD and Professor Frederik Giesel, MD are responsible for planning and organization of the clinical trial that suggest pet ct imaging using 68Ga-labelled PSMA-11 could transform treating prostate cancer.
    Professor Klaus Kopka, MD (left) and Professor Frederik Giesel, MD
    Giesel explains that 68Ga-labelled PSMA-11 is more sensitive than the choline tracer for diagnosing recurrent prostate cancer.

    On the way to being included in clinical guidelines

    Professor Frederik Giesel, MD, Vice chair of the Nuclear Medicine department and clinical trial director, University Hospital Heidelberg, Germany
    PSMA is not just an excellent candidate for pet ct imaging; together with a therapeutic radionuclide it can also be used for treating prostate cancer.

    Trial will be launched in 2017

    Professor Klaus Kopka, MD, Head of Radiopharmaceutical Chemistry, DKFZ Heidelberg, Germany

    “With this academically funded study we also want to give something back to the healthcare system and society. We have high expectations. Then we’ll see what happens.”

    Professor Klaus Kopka, MD, Head of Radiopharmaceutical Chemistry, DKFZ Heidelberg, Germany

    More Information

    By Hildegard Kaulen

    Hildegard Kaulen, PhD, is a molecular biologist. Following positions at Rockefeller University in New York and Massachusetts General Hospital in Boston, she now works as a freelance science journalist for newspapers and scientific magazines.

    1. 68Ga-labelled PSMA-11 referenced herein is not currently recognized by the US FDA as being safe and effective, and Siemens does not make any claims regarding its use.

    2. Afshar-Oromieh, A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol I 41, 11–20 (2014).

    3. Schwenck, J. et al. Comparison of 68Galabelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol I 44, 92–101 (2016).

    4. Perera, M. et al. Sensitivity, Specificity, and Predictors of Positive 68Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta.

    1. The statements by Siemens’ customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.